Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 6:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–40 of 16 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Rectal Mucinous Adenocarcinoma Clear all
Completed Phase 1 Interventional
View directory record Official record
Conditions
Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer, Signet Ring Adenocarcinoma of the Colon, Signet Ring Adenocarcinoma of the Rectum, Stage IIIA Colon Cancer, Stage IIIA Rectal Cancer, Stage IIIB Colon Cancer, Stage IIIB Rectal Cancer, Stage IIIC Colon Cancer, Stage IIIC Rectal Cancer, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Rectal Cancer
Interventions
6,8-bis(benzylthio)octanoic acid, fluorouracil, pharmacological study, laboratory biomarker analysis
Drug · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 6, 2023 · Synced May 21, 2026, 6:34 PM EDT
Terminated Phase 1 Interventional
View directory record Official record
Conditions
Carcinoma, Non-Small Cell Lung, HER2 Negative Breast Neoplasms, Ovarian Neoplasms, Uterine Cervical Neoplasms, Endometrial Neoplasms, Esophageal Neoplasms, Gastroesophageal Junction Carcinoma, Stomach Neoplasms, Colorectal Neoplasms, Exocrine Pancreatic Adenocarcinoma, Appendiceal Adenocarcinoma, Pseudomyxoma Peritonei
Interventions
SGN-STNV
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
12
States / cities
Los Angeles, California • San Francisco, California • Gainesville, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2025 · Synced May 21, 2026, 6:34 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Peritoneal Cancer, Pseudomyxoma Peritonei, Mucinous Adenocarcinoma, Mucinous Tumor, Colorectal Cancer, Gastric Cancer, Primary Peritoneal Carcinoma, Mesothelioma
Interventions
nanoliposomal irinotecan
Drug
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
Lexington, Kentucky • Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated May 5, 2022 · Synced May 21, 2026, 6:34 PM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Peritoneal Carcinomatosis
Interventions
Mitomycin C, flat dose 40 mg, Mitomycin C, weight-based dose 12.5 mg/m2
Drug
Lead sponsor
Prakash Pandalai
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
2
States / cities
Lexington, Kentucky • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced May 21, 2026, 6:34 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Adenocarcinoma of the Rectum, Mucinous Adenocarcinoma of the Rectum, Signet Ring Adenocarcinoma of the Rectum, Stage IIA Rectal Cancer, Stage IIB Rectal Cancer, Stage IIC Rectal Cancer, Stage IIIA Rectal Cancer, Stage IIIB Rectal Cancer, Stage IIIC Rectal Cancer
Interventions
fluorouracil, oxaliplatin, radiation therapy, leucovorin calcium, therapeutic conventional surgery
Drug · Radiation · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 9, 2013 · Synced May 21, 2026, 6:34 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer, Signet Ring Adenocarcinoma of the Colon, Signet Ring Adenocarcinoma of the Rectum, Stage IIIA Colon Cancer, Stage IIIA Rectal Cancer, Stage IIIB Colon Cancer, Stage IIIB Rectal Cancer, Stage IIIC Colon Cancer, Stage IIIC Rectal Cancer, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Rectal Cancer
Interventions
erlotinib hydrochloride, fluorouracil, leucovorin calcium, oxaliplatin, bevacizumab
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 29, 2013 · Synced May 21, 2026, 6:34 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Peritoneal Carcinomatosis, Colorectal Cancer, Appendiceal Cancer, Peritoneal Mesothelioma, Pseudomyxoma Peritonei, Gastric Cancer
Interventions
HIPEC, Mitomycin C
Procedure · Drug
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2024
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Oct 23, 2024 · Synced May 21, 2026, 6:34 PM EDT
Recruiting Phase 4 Interventional
View directory record Official record
Conditions
Motor Function, Cognitive Function, Contrast Media
Interventions
Motor Tests, Cognitive Tests, Unenhanced-MRI of the brain, Gadolinium Measurements, Gadoxetate disodium, Gadobenate dimeglumine, Gadodiamide, Gadoterate meglumine, Gadobutrol, Gadoteridol
Procedure · Drug
Lead sponsor
Guerbet
Industry
Eligibility
18 Years to 64 Years
Enrollment
2,076 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
16
States / cities
Scottsdale, Arizona • New Haven, Connecticut • Chicago, Illinois + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced May 21, 2026, 6:34 PM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum
Interventions
Nivolumab, Ipilimumab
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 19, 2022 · Synced May 21, 2026, 6:34 PM EDT
Terminated Phase 1 Interventional
View directory record Official record
Conditions
Adenocarcinoma of the Pancreas, Adenocarcinoma of the Stomach, BRCA1 Mutation Carrier, BRCA2 Mutation Carrier, Ovarian Mucinous Cystadenocarcinoma, Recurrent Breast Cancer, Recurrent Colon Cancer, Recurrent Gastric Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Ovarian Germ Cell Tumor, Recurrent Pancreatic Cancer, Recurrent Rectal Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage IV Colon Cancer, Stage IV Gastric Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Ovarian Germ Cell Tumor, Stage IV Pancreatic Cancer, Stage IV Rectal Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
veliparib, capecitabine, oxaliplatin, pharmacological study, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 1, 2014 · Synced May 21, 2026, 6:34 PM EDT
Recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Colorectal Cancer, Cholangiocarcinoma, Appendiceal Adenocarcinoma, Pancreatic Adenocarcinoma, Gastric Adenocarcinoma, Endometrial Adenocarcinoma, Triple Negative Breast Cancer, Ovarian Cancer, Prostate Cancer
Interventions
APL-5125
Drug
Lead sponsor
Apollo Therapeutics Ltd
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
9
States / cities
Duarte, California • Irvine, California • Sarasota, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced May 21, 2026, 6:34 PM EDT
Terminated Phase 1 Interventional Results available
View directory record Official record
Conditions
Liver Metastases, Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer, Signet Ring Adenocarcinoma of the Colon, Signet Ring Adenocarcinoma of the Rectum, Stage IV Colon Cancer, Stage IV Rectal Cancer
Interventions
irinotecan-eluting beads, hepatic artery embolization
Combination Product · Procedure
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 19, 2021 · Synced May 21, 2026, 6:34 PM EDT
Terminated Phase 1 Interventional
View directory record Official record
Conditions
Colon Mucinous Adenocarcinoma, Colon Signet Ring Cell Adenocarcinoma, Rectal Mucinous Adenocarcinoma, Rectal Signet Ring Cell Adenocarcinoma, Recurrent Colon Carcinoma, Recurrent Rectal Carcinoma, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Rectal Cancer
Interventions
Cetuximab, Gamma-Secretase Inhibitor RO4929097, Laboratory Biomarker Analysis, Pharmacological Study
Biological · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 17, 2015 · Synced May 21, 2026, 6:34 PM EDT
Not listed Phase 2 Interventional
View directory record Official record
Conditions
Mucinous Adenocarcinoma of the Rectum, Signet Ring Adenocarcinoma of the Rectum, Stage IIA Rectal Cancer, Stage IIB Rectal Cancer, Stage IIC Rectal Cancer, Stage IIIA Rectal Cancer, Stage IIIB Rectal Cancer, Stage IIIC Rectal Cancer
Interventions
bevacizumab, oxaliplatin, leucovorin calcium, fluorouracil, laboratory biomarker analysis
Biological · Drug · Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 8, 2022 · Synced May 21, 2026, 6:34 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Adenocarcinoma of the Rectum, Mucinous Adenocarcinoma of the Colon, Recurrent Colon Cancer, Recurrent Rectal Cancer, Signet Ring Adenocarcinoma of the Colon, Stage IV Colon Cancer, Stage IV Rectal Cancer
Interventions
cetuximab, bevacizumab, oxaliplatin, leucovorin calcium, fluorouracil
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jul 26, 2015 · Synced May 21, 2026, 6:34 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Colon Mucinous Adenocarcinoma, Colon Signet Ring Cell Adenocarcinoma, Rectal Mucinous Adenocarcinoma, Rectal Signet Ring Cell Adenocarcinoma, Recurrent Colon Carcinoma, Recurrent Rectal Carcinoma, Stage IIIA Colon Cancer, Stage IIIA Rectal Cancer, Stage IIIB Colon Cancer, Stage IIIB Rectal Cancer, Stage IIIC Colon Cancer, Stage IIIC Rectal Cancer, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Rectal Cancer
Interventions
Akt Inhibitor MK2206, Laboratory Biomarker Analysis, Pharmacological Study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 19, 2019 · Synced May 21, 2026, 6:34 PM EDT